<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Friedreich <z:hpo ids='HP_0001251'>ataxia</z:hpo> is an <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> caused by mutations in the FXN gene that result in abnormally low levels of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> protein frataxin </plain></SENT>
<SENT sid="1" pm="."><plain>The authors recently used a lateral flow immunoassay to measure frataxin levels in a large cohort of controls, carriers, and patients with the condition </plain></SENT>
<SENT sid="2" pm="."><plain>The findings show that frataxin levels do not appreciably change over time and correlate well with GAA(1) repeat length and <z:hpo ids='HP_0011007'>age of onset</z:hpo>; thus, frataxin is a reliable and stable marker for severity of disease </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, the authors present a patient diagnosed as having Friedreich <z:hpo ids='HP_0001251'>ataxia</z:hpo> and <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> who received combined <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (Adriamycin), and <z:chebi fb="2" ids="27899">cisplatin</z:chebi> (MAP) chemotherapy over 8 months </plain></SENT>
<SENT sid="4" pm="."><plain>The authors assessed the effect of treatment on frataxin levels, blood cell counts, and clinical markers of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Results of the regimen and the use of MAP chemotherapy for treatment of <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in individuals with Friedreich <z:hpo ids='HP_0001251'>ataxia</z:hpo> are discussed </plain></SENT>
</text></document>